Company / Shareholders' Equity
SAB Biotherapeutics, Inc. Shareholders' Equity History
FY2021-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Shareholders' Equity
$26.0M
FY2025
5-year range
$7.7M / $57.3M
FY2021-FY2025
Trend
-54.7%
vs FY2024
Sector context
Sector data unavailable
Latest sector comparison
What the data says
Shareholders' Equity has fluctuated over the past 5 years, ranging from $8M in FY2021 to $57M in FY2024.
Based on SEC 10-K filings.
$26M in FY2025 with a 3-year CAGR of -12.7%.
Declined from $31M to $26M over the past 2 years.
Shareholders' Equity over time
Growth rates
- 3-Year CAGR
- -12.7%
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Key checks
Key Insights
- 3-year CAGR of -12.7%, indicating a declining trend.
- In FY2025, shareholders' equity decreased 54.7% year-over-year.
- Peak shareholders' equity was recorded in FY2024.
- Lowest shareholders' equity in the period was in FY2021.
Company context
Key Data Points
- Low Piotroski F-Score: 2/9 (multiple financial health concerns)
- Altman Z-Score -0.31 (distress zone, below 1.8 threshold)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Shareholders' EquityValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $26.0M | -54.7% |
| FY2024 | $57.3M | +84.5% |
| FY2023 | $31.1M | -20.4% |
| FY2022 | $39.0M | +407.0% |
| FY2021 | $7.7M | - |
As of FY2025 · SEC 10-K · Updated Jun 28, 2026